secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001104659-24-064781
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports 83% confirmed ORR in RAMP 205 dose level 1 for first-line metastatic pancreatic cancer
--------------------------------------------------------------------------------

- 83% (5/6) confirmed partial response in dose level 1 cohort; dose cleared after one DLT.
- 41 patients enrolled across 4 dose/schedule cohorts of avutometinib+defactinib+gemcitabine+nab-paclitaxel.
- 21 of 26 evaluable patients had reduction in target lesion sum of diameters as of May 14, 2024 cutoff.
- 12 patients experienced SAEs (11 grade ≥3); 2 discontinued due to treatment-emergent AEs.
- Investor call on May 24, 2024 to discuss these data and rolling NDA submission in recurrent KRAS mutant LGSOC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465924064781/0001104659-24-064781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465924064781/tm2415352d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-064781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer